Overall, MASLD population (n. 466) compared to age- (66.71 vs 65.35 years; p: ns) and sex-matched (male sex 58.1 vs 51.38%; p: ns) controls (n. 73) presents higher mean BMI (30.52 vs 23.32 kg/m2; p: 0.021), GGT (83.60 vs 55.96 U/L; p: 0.025), glycaemia (116.85 vs 96.77 mg/dL; p < 0.0001), LSM (13.21 vs 5.08 kPa; p < 0.0001), FIB-4 (3.29 vs 2.81; p: 0.018), higher rates of diabetes (46.4 vs 13.84%; p < 0.0001), hypertension (72.0 vs 60.93%; p: 0.039), metabolic syndrome (41.3 vs 13.2%; p < 0.0001) and PNPLA3 dominant genetic profile (CG + GG) (56.8 vs 37.93%; p: 0.035). This evidence concerns the gene PNPLA3 and metabolic syndrome.